Janney Montgomery Scott Reiterates “Buy” Rating for Harvard Bioscience (HBIO)

Share on StockTwits

Janney Montgomery Scott reaffirmed their buy rating on shares of Harvard Bioscience (NASDAQ:HBIO) in a research report report published on Monday.

Separately, ValuEngine cut Harvard Bioscience from a buy rating to a hold rating in a research report on Tuesday, November 13th.

Shares of Harvard Bioscience stock opened at $4.01 on Monday. The firm has a market capitalization of $145.43 million, a PE ratio of 80.20 and a beta of 1.38. The company has a quick ratio of 1.49, a current ratio of 2.83 and a debt-to-equity ratio of 0.73. Harvard Bioscience has a 12 month low of $2.75 and a 12 month high of $6.70.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. First Light Asset Management LLC boosted its position in Harvard Bioscience by 5.4% during the third quarter. First Light Asset Management LLC now owns 6,270,115 shares of the medical instruments supplier’s stock valued at $32,918,000 after purchasing an additional 319,101 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Harvard Bioscience by 2.4% during the third quarter. Dimensional Fund Advisors LP now owns 1,984,029 shares of the medical instruments supplier’s stock valued at $10,416,000 after purchasing an additional 46,089 shares during the last quarter. Marshall Wace LLP acquired a new stake in Harvard Bioscience during the third quarter valued at $123,000. Royce & Associates LP boosted its position in Harvard Bioscience by 2.2% during the third quarter. Royce & Associates LP now owns 1,599,700 shares of the medical instruments supplier’s stock valued at $8,398,000 after purchasing an additional 34,700 shares during the last quarter. Finally, Northern Trust Corp boosted its position in Harvard Bioscience by 339.6% during the second quarter. Northern Trust Corp now owns 391,154 shares of the medical instruments supplier’s stock valued at $2,093,000 after purchasing an additional 302,184 shares during the last quarter. 75.05% of the stock is owned by hedge funds and other institutional investors.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation instruments that are marketed under the Biochrom, Libra, WPA, BioDrop, Hoefer, Scie-plas, and BTX brand names.

Read More: Special Dividends

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Analyzing Webster Financial  & Cadence Bancorp
Analyzing Webster Financial & Cadence Bancorp
Financial Analysis: CIBT Education Group  versus OneSmart International Edun Gr
Financial Analysis: CIBT Education Group versus OneSmart International Edun Gr
Metropolitan Life Insurance Co. NY Has $130,000 Stake in PC Connection, Inc.
Metropolitan Life Insurance Co. NY Has $130,000 Stake in PC Connection, Inc.
Metropolitan Life Insurance Co. NY Grows Holdings in PetIQ Inc
Metropolitan Life Insurance Co. NY Grows Holdings in PetIQ Inc
MetLife Investment Advisors LLC Has $209,000 Stake in Calix Inc
MetLife Investment Advisors LLC Has $209,000 Stake in Calix Inc
MetLife Investment Advisors LLC Has $214,000 Holdings in RadNet Inc.
MetLife Investment Advisors LLC Has $214,000 Holdings in RadNet Inc.


 
© 2006-2019 Zolmax.